The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL. Additionally, this study will assess the correlation between QoL, obtained from commonly used and validated questionnaires, and the perceptions of both patients and caregivers respectively., obtain from a 10-point scale and a comment box.

开始日期2024-09-26

申办/合作机构

Peripharm, Inc.

NCT06311864 / RecruitingN/A

Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia with Daridorexant in Canada

The purpose of this observational study is to evaluate the impact of daridorexant on quality of life, work productivity and insomnia symptoms in Canadian adults suffering from insomnia.

开始日期2024-06-20

申办/合作机构

Peripharm, Inc.

[+1]

NCT05556564 / CompletedN/A

The Impact of Migraine on Canadians' Productivity: A Real-World Pharmacy-Based Study

This is a cross-sectional, real-world observational, community pharmacy-based study in which adults treated with a triptan for their migraine will self-report productivity and activity impairment using a web-based portal or paper-based questionnaire.

开始日期2022-10-31

申办/合作机构

Peripharm, Inc.

100 项与 Peripharm, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Peripharm, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Peripharm, Inc. 相关的文献（医药）

2023-04-24·Current oncology (Toronto, Ont.)

Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.

Article

作者: Guinan, Kimberly ; Aw, Andrew ; Owen, Carolyn ; Fleury, Isabelle ; Banerji, Versha ; Lachaine, Jean

BACKGROUNDContinuous oral targeted therapies (OTT) represent a major economic burden on the Canadian healthcare system, due to their high cost and administration until disease progression/toxicity. The recent introduction of venetoclax-based fixed-duration combination therapies has the potential to reduce such costs. This study aims to estimate the prevalence and the cost of CLL in Canada with the introduction of fixed OTT.METHODSA state transition Markov model was developed and included five health states: watchful waiting, first-line treatment, relapsed/refractory treatment, and death. The number of CLL patients and total cost associated with CLL management in Canada for both continuous- and fixed-treatment-duration OTT were projected from 2020 to 2025. Costs included drug acquisition, follow-up/monitoring, adverse event, and palliative care.RESULTSThe CLL prevalence in Canada is projected to increase from 15,512 to 19,517 between 2020 and 2025. Annual costs were projected at C$880.7 and C$703.1 million in 2025, for continuous and fixed OTT scenarios, respectively. Correspondingly, fixed OTT would provide a total cost reduction of C$213.8 million (5.94%) from 2020 to 2025, compared to continuous OTT.CONCLUSIONSFixed OTT is expected to result in major reductions in cost burden over the 5-year projection, compared to continuous OTT.

2023-01-01·ClinicoEconomics and outcomes research : CEOR

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.

Article

作者: Hegele, Robert A ; Leiter, Lawrence A ; Gregoire, Jean C ; Charron, Jean-Nicolas ; Lachaine, Jean

BackgroundDespite the use of statins, many patients with cardiovascular disease (CVD) have persistent residual risk. In a large Phase III trial (REDUCE-IT), icosapent ethyl (IPE) was shown to reduce the first occurrence of the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina.MethodsWe conducted a cost-utility analysis comparing IPE to placebo in statin-treated patients with elevated triglycerides, from a publicly funded, Canadian healthcare payer perspective, using a time-dependent Markov transition model over a 20-year time horizon. We obtained efficacy and safety data from REDUCE-IT, and costs and utilities from provincial formularies and databases, manufacturer sources, and Canadian literature sources.ResultsIn the probabilistic base-case analysis, IPE was associated with an incremental cost of $12,523 and an estimated 0.29 more quality-adjusted life years (QALYs), corresponding to an incremental cost-effectiveness ratio (ICER) of $42,797/QALY gained. At a willingness-to-pay of $50,000 and $100,000/QALY gained, there is a probability of 70.4% and 98.8%, respectively, that IPE is a cost-effective strategy over placebo. The deterministic model yielded similar results. In the deterministic sensitivity analyses, the ICER varied between $31,823-$70,427/QALY gained. Scenario analyses revealed that extending the timeframe of the model to a lifetime horizon resulted in an ICER of $32,925/QALY gained.ConclusionIPE represents an important new treatment for the reduction of ischemic CV events in statin-treated patients with elevated triglycerides. Based on the clinical trial evidence, we found that IPE could be a cost-effective strategy for treating these patients in Canada.

2022-11-15·Blood

The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab

作者: Bull, Sarah-Jane ; Lachaine, Jean ; Banerji, Versha ; Barakat, Stéphane ; Hillis, Christopher M. ; Paul Roc, Nancy ; Tankala, Dipti ; Guinan, Kimberly

100 项与 Peripharm, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Peripharm, Inc. 相关的转化医学

登录后查看更多信息